Lim, Jamie L.
Augustinus, Roy
Plomp, Jaap J.
Roya-Kouchaki, Kasra
Vergoossen, Dana L. E.
Fillié-Grijpma, Yvonne
Struijk, Josephine
Thomas, Rachel
Salvatori, Daniela
Steyaert, Christophe
Blanchetot, Christophe
Vanhauwaert, Roeland
Silence, Karen
van der Maarel, Silvère M.
Verschuuren, Jan J.
Huijbers, Maartje G.
Funding for this research was provided by:
Prinses Beatrix Spierfonds (W.OR-19.13)
Argenx
Leids Universitair Medisch Centrum (OIO)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (VENI 0915016181 0040)
Top Sector Life Sciences & Health to Samenwerkende Gezondheidsfondsen (LSHM18055-SGF, LSHM19130)
Article History
Received: 20 January 2023
Accepted: 30 March 2023
First Online: 8 May 2023
Competing interests
: M.G.H., J.J.P., S.M.M. and J.J.V. are co-inventors on two patent applications on MuSK-related research. LUMC, M.G.H., J.J.P., S.M.M. and J.J.V. receive license income from these patents. LUMC receives royalties for a diagnostic MuSK ELISA. C.S., C.B., R.V., and K.S., are (former) employees/consultants of argenx BV and some are holders of employee equity in argenx SE. Argenx exclusively owns two patent families which have been filed by applicant ‘Academisch Ziekenhuis Leiden (h.o.d.n. LUMC)’. The two patent families WO2020/055241 and WO2020/055240 are directed to respectively agonistic and antagonistic antibodies binding to Ig-like 1 domain of MuSK. ‘argenx IIP BV’ and ‘Academisch Ziekenhuis Leiden’ are co-applicants on a patent family (WO2021/180676) directed to antibodies binding to Ig-like 1 domain of MuSK, and therapeutic uses thereof. No other authors have conflicts of interest.